Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function (original) (raw)

Thromb Haemost 2005; 94(05): 1019-1027
DOI: 10.1160/TH05-02-0115

Platelets and Blood Cells

Schattauer GmbH

Authors

• Fadila Guessous
  1Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia, USA
• Marek Marcinkiewicz
  1Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia, USA
• Renata Polanowska-Grabowska
  1Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia, USA
• Tiffany R. Keepers
  2Division of Nephrology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA
• Tom Obrig
  2Division of Nephrology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA
• Adrian R. L. Gear
  1Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia, USA

Financial support: This study was supported by Public Health Service Grants DK59004 (to A.R.L. Gear) and AI 24431 (to T. Obrig).

Further Information

Publication History

Received: 16 February 2005

Accepted after resubmission: 08 August 2005

Publication Date:
14 December 2017 (online)

Summary

Platelet and monocyte activation may contribute to hemolytic anemia, thrombocytopenia and renal failure associated with the hemolytic uremic syndrome (HUS) caused by Escherichia coli O157:H7. Since Shiga toxins (Stxs) and lipopolysaccharide (LPS) from this bacterium are implicated in the pathogenesis of HUS, we examined whether stimulation of THP-1 human monocytic cells by Shiga toxin 2 (Stx2) and LPS can lead to the activation of platelet function. We now show that Stx2 caused THP-1 cells to release the chemokines IL-8, MDC, and RANTES and that the presence of LPS further stimulated this release. IL-8 was produced in greatest amount and was an effective co-agonist for inducing platelet aggregation. Primary human monocytes also released large amounts of IL-8 in response to LPS and Stx2. Factors released by THP-1 cells exposed to Stx2 and LPS activated platelet function as evidenced by increased aggregation, serotonin secretion, P-selectin exposure and by the formation of stable platelet-monocyte aggregates. Our data therefore show that monocytes exposed to E. coli-derived Stx2 and LPS release factors which activate platelet function.

Keywords

Shiga toxin - lipopolysaccharide (LPS) - platelets - aggregation - chemokines - monocytes (THP-1) - secretion - hemolytic uremic syndrome (HUS) - IL-8 - RANTES

• References

• 1 Gasser C, Gautieer E, Steck A. et al. Hämolytischuramische Syndrome: Bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytishen Anämien. Schweiz Med Wochenschr 1955; 85: 905-909.
• 2 Huppertz H, Busch D, Schmidt H. et al. Diarrhea in young children associated with Escherichia coli non-O157 organisms that produce Shiga-like toxin. J Pediatr 1996; 128: 341-6.
• 3 Ludwig K, Sarkim V, Bitzan M. et al. Shiga toxinproducing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol 2002; 40: 1773-82.
• 4 Blackall DP, Marques MB. Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation. Am J Clin Pathol. 2004 121 Suppl S81-88.
• 5 Appiani AC, Edefonti A, Bettinelli A. The relationship between plasma levels of the factor VIII complex and platelet release products β-thromboglobulin and platelet factor 4) in children with the hemolytic-uremic syndrome. Clin Nephrol 1982; 17: 195-9.
• 6 Walters MD, Levin M, Smith C. et al. Intravascular platelet activation in the hemolytic uremic syndrome. Kidney Int 1988; 33: 107-15.
• 7 Yoshimura K, Fujii J, Yutsudo T. et al. No direct effects of Shiga toxin 1 and 2 on the aggregation of human platelets in vitro. Thromb Haemost 1998; 80: 529-30.
• 8 Thorpe CM, Flaumenhaft R, Hurley B. et al. Shiga toxins do not directly stimulate alpha-granule secretion or enhance aggregation of human platelets. Acta Haematol 1999; 102: 51-5.
• 9 Viisoreanu D, Polanowska-Grabowska R, Suttitanamongkol S. et al Human platelet aggregation is not altered by Shiga toxins 1 or 2. Thromb Res 2000; 98: 403-10.
• 10 Koster F, Levin J, Walker L. et al. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med 1978; 298: 927-33.
• 11 Bitzan M, Moebius E, Ludwig K. et al. High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic uremic syndrome. J Pediatr 1991; 119: 380-5.
• 12 Karpman D, Connell H, Svensson M. et al. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 1997; 175: 611-20.
• 13 van Setten PA, Monnens LA, Verstraten RG. et al. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 1996; 88: 174-83.
• 14 Harrison LM, van Haaften WCE, Tesh VL. Regulation of proinflammatory cytokine expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic cell line THP-1. Infect Immun 2004; 72: 2618-27.
• 15 Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335-50.
• 16 Shenkman B, Brill A, Brill G. et al. Differential response of platelets to chemokines: RANTES non-competitively inhibits stimulatory effect of SDF-1alpha. J Thromb Haemost 2004; 2: 154-60.
• 17 Suttitanamongkol S, Gear AR. ADP receptor antagonists inhibit platelet aggregation induced by the chemokines SDF-1, MDC and TARC. FEBS Lett 2001; 490: 84-7.
• 18 Gear AR. Rapid reactions of platelets studied by a quenched-flow approach: aggregation kinetics. J Lab Clin Med 1982; 100: 866-86.
• 19 Goldsmith HL, Turitto VT. Rheological aspects of thrombosis and haemostasis: basic principles and applications. ICTH-Report–Subcommittee on Rheology of the International Committee on Thrombosis and Haemostasis Thromb Haemost 1986; 55: 415-35.
• 20 Jones GD, Carty DJ, Freas DL. et al. Effects of separate proteolytic and high-affinity binding activities of human thrombin on rapid platelet activation. A quenched-flow study. Biochem J 1989; 262: 611-6.
• 21 Karmali MA, Petric M, Lim C. et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producingEscherichia coli . J Infect Dis 1985; 151: 775-82.
• 22 Taylor FB, Tesh VL, DeBault L. et al. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 1999; 154: 1285-99.
• 23 Ghosh SA, Polanowska-Grabowska R, Fujii J. et al. Shiga toxin binds to activated platelets. J Thromb Haemost 2004; 2: 499-506.
• 24 Brueckmann M, Hoffmann U, DeRossi L. et al. Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine 2004; 26: 106-13.
• 25 Sakamoto H, Aikawa M, Hill CC. et al. Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension. Circulation 2001; 104: 109-14.
• 26 Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001; 86: 214-21.
• 27 Karpman D, Papadopoulou D, Nilsson K. et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 2001; 97: 3100-8.
• 28 Baltus T, von Hundelshausen P, Mause SF. et al. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol 2005; 78: 435-41.
• 29 Eriksson EE. Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects. Curr Opin Lipidol 2004; 15: 553-8.
• 30 Henn V, Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
• 31 Leytin V, Shakoor S, Mody M. Sepsis- and endotoxemia- generated cytokines do not trigger activation of human platelets. Crit Care Med 2002; 30: 27713.
• 32 Gear AR, Suttitanamongkol S. Viisoreanu et al. Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood 2001; 97: 937-45.
• 33 Marcus AJ, Broekman MJ, Drosopoulos JH. et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997; 99: 1351-60.
• 34 Robson SC, Kaczmarek E, Siegel JB. et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185: 153-63.
• 35 Steen VM, Holmsen H, Aarbakke G. The plateletstimulating effect of adrenaline through alpha 2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce human platelet activation in vitro. Thromb Haemost 1993; 70: 506-13.
• 36 Clemetson KJ, Clemetson JM, Proudfoot AE. et al. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000; 96: 4046-54.
• 37 Huo Y, Schober A, Forlow SB. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-7.
• 38 Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002; 105: 2130-2.
• 39 Gawaz M, Dickfeld T, Bogner C. et al. Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997; 23: 379-85.
• 40 Nieuwland R, Berckmans RJ, McGregor S. et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930-5.
• 41 Ogura H, Kawasaki T, Tanaka H. et al. Activated platelets enhance microparticle formation and plateletleukocyte interaction in severe trauma and sepsis. J Trauma 2001; 50: 801-9.
• 42 Brass L, Molino M. Protease-activated G proteincoupled receptors on human platelets and endothelial cells. Thromb Haemost 1997; 78: 234-41.
• 43 Schmid DI, Kohan DE. Effect of shigatoxin-1 on arachidonic acid release by human glomerular epithelial cells. Kidney Int 2001; 60: 1026-36.
• 44 Tonshoff B, Momper R, Kuhl PG. et al. Increased thromboxane biosynthesis in childhood hemolytic uremic syndrome. Kidney Int 1990; 37: 1134-41.
• 45 Noris M, Benigni A, Siegler R. et al. Renal prostacyclin biosynthesis is reduced in children with hemolytic- uremic syndrome in the context of systemic platelet activation. Am J Kidney Dis 1992; 20: 144-9.
• 46 Harrison LM, van den Hoogen C, van Haaften WC. et al. Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides. Infect Immun 2005; 73: 403-12.
• 47 Montrucchio G, Bosco O, Del Sorbo L. et al. Mechanisms of the priming effect of low doses of lipopolysaccharides on leukocyte-dependent platelet aggregation in whole blood. Thromb Haemost 2003; 90: 872-81.